Coronary/Structural Heart

Tenax Announces Late-Breaking Results from the HELP Study Accepted for Presentation at the Heart Failure Society of America (HFSA) Annual Scientific Meeting

HELP Study results, evaluating levosimendan in patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF), will be presented during a Late-Breaking Clinical Trial session during the HFSA Annual Scientific Meeting MORRISVILLE, N.C.–(BUSINESS WIRE)–Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing […]

Philips expands its dedicated cardiovascular ultrasound offering by launching Affiniti CVx for increased productivity

Philips introduces Affiniti CVx and Release 7.0 of EPIQ CVx with breakthrough interventional and productivity features to support cardiology departments managing everyday challenges Philips debuts impactful solutions in cardiology at ESC 2020 (Aug 29 – Sept 1) Amsterdam, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health […]

Matinas BioPharma Completes Enrollment of ENHANCE-IT Study of MAT9001 Against Vascepa®

Topline data expected first quarter 2021 BEDMINSTER, N.J., Aug. 27, 2020 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that it has completed enrollment in the ENHANCE-IT Study (Pharmacodynamic Effects of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids to ENHANCE Efficacy in Adults with Hypertriglyceridemia), a […]

NILEMDO® Delivers Significant Cholesterol Lowering in Addition to Statin Therapy Which is Maintained During 2.5 Years of Treatment

NILEMDO® (bempedoic acid) is a new, first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering treatment that significantly reduces LDL-C on top of statins and other lipid-lowering therapies1 Bempedoic acid acts on the well-known cholesterol synthesis pathway, upstream of the statin target in the liver1 Due to its unique mechanism of action, bempedoic […]

Philips debuts impactful solutions in cardiology at ESC 2020 to deliver better patient care with greater efficiency

onnected cardiology solutions help physicians elevate clinical confidence, improve patient and staff experience, and improve outcomes Amsterdam, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, is showcasing its latest cardiac care innovations at the European Society of Cardiology ESC Congress 2020 (August 29 – September 1). During […]

Northwestern Medicine Celebrates 2000th Transcatheter Heart Valve Procedure

Minimally invasive treatment revolutionized cardiac medicine, replacing open-heart surgery for many patients CHICAGO, Aug. 26, 2020 /PRNewswire/ — Northwestern Medicine Bluhm Cardiovascular Institute physicians recently completed their 2000th transcatheter heart valve procedure, a milestone innovation that has shifted valve repair and replacement from operating room to catherization lab, dramatically reducing procedural time, recovery […]

New Amgen Data To Be Presented At ESC Congress 2020 Highlighting Repatha® (evolocumab) Efficacy In High-Risk Patient Populations

Repatha (Evolocumab) Late-Breaking Data Showcase First Phase 3 Study of a PCSK9 Inhibitor in Pediatric Heterozygous Familial Hypercholesterolemia New Data Highlight Gaps in Treating High LDL-C to Clinical Treatment Guidelines in a Large Cohort of European, High-Risk CVD Patients THOUSAND OAKS, Calif., Aug. 25, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the […]

Medtronic Evolut TAVR System Receives Updated U.S. Labeling Revising Precaution for Treatment of Low-Risk Patients with Bicuspid Aortic Stenosis

Revised Commercial Labeling Broadens Patient Population Who May be Candidates for Transcatheter Aortic Valve Replacement (TAVR) DUBLIN, Aug. 21, 2020 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) has approved revised commercial labeling for the Evolut™ TAVR platform […]

Medicure Announces AGGRASTAT® Shows Promise in Treating Thrombotic Complications Due to COVID-19 in Early Clinical Reports

WINNIPEG, MB, Aug. 24, 2020 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company“) (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, is reporting that early investigator sponsored clinical reports evaluating the efficacy of AGGRASTAT® (tirofiban hydrochloride) show promise for preventing and treating thrombotic complications due to COVID-19. AGGRASTAT® is not currently indicated for use in patients with COVID-19. […]

Jasper Capital Announces First Successful Implant of Guardian® Heart Attack Alarm System in Patients

First and Only Technology Providing Continuous Real-Time Alerting of Heart Attacks SINGAPORE–(BUSINESS WIRE)–Jasper Capital Ltd www.jasperCL.com (“Jasper”), a private equity fund with operations in Singapore and Silicon Valley, today announced the first successful implant of an implantable commercial heart attack alarm system, called the Guardian® system, developed by its portfolio company, Angel […]